glp 1 for iih and The effect of GLP-1 agonist on idiopathic intracranial hypertension: a systematic review meta-analysis Infographic: Landmark trials in Neuro-Ophthalmology—results – Effect of glucagon like peptide-1

N.KasiskeB

This screening is a fundamental safety measure and should be documented in the patient's medical records

However, exceeding 5000 IU weekly increases risks without proportional benefits for most users

176 GLP-1RAs and diseases As a rising star in recent years, GLP-1RAs are not only effective in metabolic diseases but also play a role in non-metabolic disorders, affecting multiple systems including the musculoskeletal, nervous, cardiovascular, and digestive systems, and can even have implications in oncological diseases

Eccogene announced that it entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will develop and commercialize Eccogenes small molecule GLP-1 receptor agonist ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities